Replies to post #77936 on Biotech Values

[DewDiligence]

MDCO offered the USPTO what was tantamount to a $60M bribe to get Congress to enact an exemption re the filing deadline, but Congress wouldn’t bite.

So now, the company’s shills on Wall Street are saying that a generic version of Angiomax is exceedingly difficult to manufacture. As you can tell from my prior posts, I don’t buy the argument.

[exwannabe]

Re: Lawsuit on MDCO;s late patent extension filing.

"Wow. Not sure, but that sounds like a fine shareholder derivative suit."

Is that really true?

Who knows where the ball was dropped. For several years I had a job at a public tech company where one minor responsibility was patents. Every so often I would get letters from our attorneys that it was time to re-up, If I dropped the ball on one of these by mistake, I would think somebody might be real pissed. But it's hard to see a shareholder lawsuit,

If the pattent attorney's dropped the ball I could see a suit against them.

There is just ZERO chance that the company was not going to re-uo and changed there mind to late. You re-up even moderately bogus pattents.

[genisi]

Wow. Not sure, but that sounds like a fine shareholder derivative suit.

Since it was the company's patent lawyers mistake, I was expecting a malpractice suit. Maybe no suit was filed because MDCO has not yet lost anything and they all wait for generic versions of Angiomax to enter the market.